, at the start of courses 2 and 6, we obtained the ATRA AUCs equivalent to the ones achieved on day 1 of course 1. In conclusion, our results showed that ATRA alone appeared to be unable to control the WBC expansion in the CML patients in chronic phase. Moreover, it did not induce any remarkable cytoreductive effects on the platelet count and on the hemoglobin level. The major interest of ATRA would be in combination with other therapies. If ATRA was given in combination with IFN␣ or other agents, dose reduction of these would not be planned. On the basis of the pharmacokinetic profile, ATRA should be administered intermittently rather than continuously.
Introduction
Due to the remarkable activity of all-trans retinoic acid (ATRA) in patients with acute promyelocytic leukemia (APL), [1] [2] [3] [4] [5] [6] increasing attention has recently been focused on the use of ATRA as a potential antileukemic agent in other hematological diseases. For this reason, ATRA alone or in combination with other agents has been tested in myelodysplastic syndromes, [7] [8] [9] in cutaneous T cell lymphomas 10, 11 and in multiple myeloma. 12, 13 The clinical use of ATRA in chronic myeloid leukemia (CML) was first reported by Wiernik et al, 14 who described a partial remission in a patient with CML in the Correspondence: D Russo, Clinica Ematologica, Policlinico Universitario, Piazza S Maria della Misericordia, Udine, Italy; Fax: 39 432/559661 Received 24 July 1997; accepted 8 January 1998 blastic phase (BP) after treatment with ATRA. Although this patient lacked the t(15;17) translocation and the PML-RAR␣ rearrangement, he was selected for treatment with ATRA because many of his blast cells resembled the leukemic promyelocytes observed in APL; moreover the CML colony-forming cells (CML-CFCs) were strongly inhibited by ATRA in the semisolid culture. 15 This in vitro observation appears to be in accordance with other preclinical data showing that the ATRA sensitivity of progenitors from CML patients in the advanced phase 16, 17 was stronger than that of progenitors from patients in the chronic one. [18] [19] [20] This finding is as yet unexplained and is apparently in contrast, not only with the knowledge that retinoids are more active in the early stage of tumorigenesis, 21, 22 but also with the more recent in vitro data indicating that ATRA, especially in combination with IFN␣, can exert significant suppressive effects on Ph+ cells from patients in the chronic phase by either inducing growth inhibition 17, 23 or apoptosis. 24 These preclinical observations suggested that ATRA could be clinically exploitable in vivo. A transient antileukemic ATRA effect was recently described in CML patients in the accelerated blastic phase 25 but, at the present time, the effects of ATRA in CML patients in the chronic phase are unknown. We therefore investigated the effects of an intermittent treatment with ATRA in a selected cohort of patients with Ph+ CML in the chronic phase. Since pharmacokinetic ATRA data in CML is not available and an intermittent schedule has never been tested for this disease, we also evaluated the pharmacokinetic profile of ATRA with the aim of achieving useful information to design the dosing regimen of future therapeutic trials with ATRA alone or in combination with other drugs.
Materials and methods

Patients
From January 1995 to June 1996, 18 patients with Ph+ CML in chronic phase were included in the study. The patients were recruited by seven hematological centers and were considered eligible if: (1) they had Ph+ CML in the first chronic phase; (2) they were older than 18 and younger than 70 years of age; (3) their ECOG performance status was 0-2; (4) they were either untreated or treated with hydroxyurea (HU) or busulfan (BUS); (5) they showed no indication for IFN␣ therapy or had discontinued IFN␣ because of toxicity, refusal or no hematological response; (6) there was no indication for bone marrow transplantation (BMT); (7) there was no associated disorder that could markedly influence the evolution of treatment or its toxicity (ie liver, renal, cardiac or psychiatric disease, diabetes, concomitant neoplasia, alcoholism); and (8) informed consent was given. As ATRA is teratogenetic a pregnancy test 450 was mandatory for fertile women. Pregnancy, lactation or refusal to use an accepted method of birth control were formal exclusion criteria. The experimental characteristics of the trial as well as the need for more frequent clinical and laboratory evaluations than are usually required, including pharmacokinetic studies, were pointed out.
Of the 18 patients, nine were male and nine female, with a median age of 58 years (range 33-70). The median time from diagnosis was 21 months (range 0-129). Three patients were untreated, while the other 15 patients had been treated with IFN␣ (one case) or HU alone (four cases), or IFN␣ and other cytotoxic agents (10 cases) including HU, BUS or cytarabine (AC). Before therapy with ATRA, 14/18 patients had received a pretreatment with HU at a dose ranging from 1 to 2 g/day for a median of 22 days (range 10-63) in order to achieve a WBC less than 10 × 10 9 /l. The patients' characteristics are reported in Table 1 .
Treatment plan Pretreatment with HU:
Patients with WBC Ͼ 10 × 10 9 /l first received treatment with HU up to 2 g/day p.o.; as soon as WBC Ͻ 10 × 10 9 /l, HU was withdrawn and treatment with ATRA was immediately started.
Treatment with ATRA:
All-trans retinoic acid (Ro 01-5488, ATRA, Vesanoid), a synthetic stereo-isomer of isotretinoin, was authorized for experimental clinical use in Ph+ CML. It was supplied free of charges from Roche SpA (Milan, Italy) in bottles containing 100 capsules (1 cp = 10 mg gelatin) for oral administration.
ATRA was given at a dose of 80 mg/m 2 /day (p.o.), divided into two equal doses after meals, for 7 consecutive days every other week for a total of 12 courses (1 course = 1 week on and 1 week off). After each course, continuation of treatment was based on WBC and/or platelet count (PLT) which were checked weekly. If WBC was Ͻ50 × 10 9 /l and/or PLT was Ͻ1500 × 10 9 /l, treatment with ATRA was continued; if WBC was Ͼ50 × 10 9 /l and/or PLT was Ͼ1500 × 10 9 /l, ATRA was stopped and the patients went off the study. At the end of the sixth course (12th week) of therapy the patients with WBC Ͻ 10 × 10 9 /l, PLT Ͻ 500 × 10 9 /l, Hb Ͼ 11 g/dl and spleen not palpable were scheduled to continue ATRA at the same dose and schedule for a further six courses. The patients who did not meet these criteria were removed from the study. At the end of the 12th course (24th week) the treatment with ATRA was discontinued and cytogenetics was checked only if WBC Ͻ 10 × 10 9 /l, PLT Ͻ 500 × 10 9 /l, Hb Ͼ 11 g/dl and spleen not palpable were maintained.
ATRA dose adjustment:
The ATRA dose was adjusted according to hematological and/or extra-hematological toxicity as follows: in the case of Hb 85-75 g/l, and/or WBC 4.0-2.0 × 10 9 /l, and/or PLT 99-50 × 10 9 /l, and/or extra-hematological toxicity grade II (WHO), ATRA was continued at 50% of the dose without stopping until recovery; in the case of Hb Ͻ 75 g/l, WBC Ͻ 2.0 × 10 9 /l, and/or PLT Ͻ 50 × 10 9 /l, and/or extra-hematological toxicity grade III (WHO), ATRA was immediately stopped until complete recovery and then it was started again at 50% of the dose (ie 40 mg/m 2 /day); in the case of extra-hematological toxicity grade IV (WHO), ATRA was permanently discontinued.
Pharmacokinetics of ATRA Pharmacokinetic profiles of ATRA were evaluated during intermittent therapy according to the following schedule:
Profile 1: on day 1, of course 1 (1st week of therapy). Profile 2: on day 7, of course 1 (1st week of therapy). Profile 3: on day 1, of course 2 (3rd week of therapy). Profile 4: on day 1, of course 6 (11th week of therapy).
Each profile consisted of seven time-points, starting immediately before the ATRA morning dose and continuing for 1, 2, 3, 4, 6 and 8 h after drug administration. Plasma samples obtained by centrifugation at 3200 g for 10 min, were protected from light to prevent ATRA photoisomerization and stored at −20°C until assayed. Plasma ATRA concentrations were determined by a modification of a previously described, high performance liquid chromatography (HPLC) method. 26 Briefly, plasma (1 ml) was treated with ethanol (2 ml) and ethylacetate (2 ml). After brief centrifugation, the supernatant was kept at 4°C. The pellet was broken and washed with ethylacetate (2 ml), and the washing was added to the supernatant. The solvent was removed under a stream of nitrogen at 35°C. The residue was dissolved in 120 l of methanol and 50 l injected into the HPLC system. The detection was done at 345 nm, with a spherical C 18 column (25 cm × 4.6 nm, 5 ) and a mobile phase of ammonium acetate buffer acetonitrile (34:66) at a flow rate of 1.8 ml/min. The limit of quantitation of our method was 5 ng/ml. The inter-intra day precision of tretinoin standards was less than 10%.
In each case, plasma concentration-time curves were fitted by means of a proper analysis program (Siphar-Kinetics; Simed, Paris, France). The time to reach peak plasma concentration (t max ), the maximum observed plasma concentration (C max), the elimination half-life (t.) and the area under the plasma drug concentration-time curve (AUC) were the pharmacokinetic parameters analyzed. The AUCs calculated by the trapezoidal rule from t 0 to t ϱ correspond to the AUC during the dosing interval, since 10-12 h after administration, plasma ATRA concentrations were below the sensitivity limit of our method.
The pharmacokinetic parameters obtained in each patient were analyzed by means of the analysis of variance (ANOVA) and the Turkey test. A P value Ͻ0.05 was considered significant.
Results
Hematological effects of ATRA
Of the 18 patients treated with ATRA, 11 (61%) went off the study before the sixth course of treatment because WBC progressively increased to more than 50 × 10 9 /l (seven cases), platelet count augmented to more than 1500 × 10 9 /l (one case), and three patients refused to continue the therapy. Five (39%) patients completed the first six courses (12 weeks) of treatment with ATRA but they were withdrawn from the study because the WBCs increased to more than 10 × 10 9 /l; the remaining two patients who had maintained WBC less than 10 × 10 9 /l and had PLT Ͻ 500 × 10 9 /l and spleen not palpable were selected to continue the ATRA treatment at the same dose and schedule for the further six courses. However, one of the two refused to continue ATRA (case No. 7), the other one (case No. 1) continued the treatment with ATRA and completed the 12th course maintaining WBC Ͻ 10 × 10 9 /l, PLT Ͻ 500 × 10 9 /l and spleen not palpable (Table 2) . At the end of the 12th course, cytogenetics was checked in this patient but the karyotypic response was absent (Ph negative metaphases = 0%). An increasing proportion of granulocytic precursors (PMC + MC%) and peripheral blasts (MB%) in the differential was observed in all 16 (89%) patients who were not able to maintain a WBC Ͻ 10 × 10 9 /l (Table 2 ). However, none of them progressed towards the accelerated blastic phase. The platelet counts doubled or increased by more than 25% in comparison with the baseline values, in six of the 16 (37.5%) patients. No significant variations of hemoglobin level were observed during the treatment in any of the patients who were treated with ATRA (Table 2) .
ATRA toxicity
The treatment with ATRA was well tolerated and only one patient discontinued the therapy because of non-hematological side-effects. Headache, xerostomia and dry skin frequently occurred, but their grade (WHO) was mild (Table 3) . In only two cases (Nos 5 and 9) was the ATRA dose reduced by 50% because of headaches (WHO grade II) ( Table 2 ). Four (22%) patients refused to continue the treatment with ATRA. Of them three patients decided to stop therapy because of the low efficiency of ATRA in controlling the WBC. The last patient (case No. 7) decided to discontinue ATRA at the sixth course of therapy because of the persistence of several sideeffects consisting of headache (WHO grade II), xerostomia (WHO grade II) and pain (WHO grade II).
ATRA pharmacokinetic results
Body systemic exposure to ATRA, as determined by the area under the plasma concentration-time curve (AUC), decreased significantly during the first course of drug administration from 678.3 ± 498.1 ng.h/ml on day 1 to 258.7 ± 272.4 ng.h/ml on day 7, with a mean decrease of 49.1%. After one week without ATRA administration the mean plasma AUC on day 1 of course 2 of therapy was not statistically different from the corresponding value observed on day 1 of course 1 (560.6 ± 390.2 vs 678.3 ± 498.1 ng·h/ml). Mean (±s.d.) C max observed were 231.3 (±143.0) ng/ml on day 1 of course 1, 96.0 (± 90.1) ng/ml on day 7 of course 1 and 232.5 (± 160.4) ng/ml on day 1 of course 2, with a statistically significant difference between day 1 and day 7 of course 1. No statistically significant differences were found in other pharmacokinetic parameters evaluated during intermittent therapy. The ATRA pharmacokinetic parameters are shown in Table 4 . An addition ATRA pharmacokinetic profile was evaluated on day 1 of course 6, in seven patients who completed the first six courses of therapy. The AUC values obtained were compared with the ones observed during course 1 on days 1 and 7 and during course 2 on day 1. A statistically significant difference was noticed by comparing the AUC value calculated on day 7 of course 1 with the AUC values obtained on days 1 of courses 1 (week 1), 2 (week 3) and 6 (week 11) of intermittent ATRA administration. The data are reported in Table 5 . We did not observe any statistically significant difference between the ATRA AUCs of the patients who had completed the first six courses of therapy and the ATRA AUCs of the patients who went off the study before the sixth course (422.2 ± 177.5 ng·h/ml vs 442.2 ± 247.2 ng·h/ml, P Ͼ 0.05).
Discussion
At present, the effects of ATRA in CML patients in the chronic phase are substantially unknown. In fact, information on the hematological and non-hematological effects of ATRA is insufficient and data on the dosing regimen is completely lacking. To answer these questions we treated 18 CML patients in the first chronic phase with ATRA at a dose of 80 mg/m 2 /day for 7 consecutive days every other week. Before starting ATRA, the majority of patients (14/18) underwent HU pretreatment with the aim of achieving WBC Ͻ 10 × 10 9 /l and reducing the potential risk of the ATRA syndrome. The choice of using a dose of ATRA higher than the one usually given in APL was arbitrary and only in part due to the in vitro observations which suggested that ATRA effects on CML progenitors were dose-dependent. Furthermore, it has to be considered that when we started the study no comparison could be made between our dosing regimen and others. The intermittent schedule of ATRA administration was chosen in an attempt to prevent the induction of pharmacokinetic resistance to ATRA, as indicated by previous observations in solid tumors. 27 As far as the hematological effects are concerned, we observed that ATRA, used as a single agent, was not able to control WBC in the majority of patients. Furthermore, it did not induce any substantial cytoreductive effects either on the platelet count or on the hemoglobin level. An increasing proportion of granulocytic precursors in the differential was observed in all of the patients who did not maintain WBC Ͻ 10 × 10 9 /l. It was impossible to establish whether that increase was spontaneous or was triggered by ATRA. The poor cytoreductive effects of ATRA observed in our patients could be influenced by the fact that most patients had a lengthy chronic phase (median time from diagnosis: 21 months). However, it cannot be excluded that the cytotoxic activity was poor because the ATRA plasma levels were lower than the ones required to control in vivo the expansion of the Ph+ clone. Our pharmacokinetic results did not show any apparent relationships between ATRA plasma levels and the time of WBC progression. In fact, we did not observe any differences between ATRA AUCs in the patients who had completed the first six courses of therapy and ATRA AUCs of the patients who went off the study before the sixth course (422.2 ± 177.5 ng·h/ml vs 442.2 ± 247.2 ng·h/ml, P Ͼ 0.05). The results of our pharmacokinetic study confirmed the reversibility of the ATRA accelerated clearance and the possibility of modulating ATRA pharmacok- a Statistically significant difference compared to day 1 course 1 (P Ͻ 0.001) and to day 1 course 2 (P Ͻ 0.05). b Statistically significant difference compared to day 1 course 1 (P Ͻ 0.001) and to day 1 course 2 (P Ͻ 0.01). inetics by altering the schedule of drug administration. 28 In our patients, the area under the concentration-time curve (AUC) decreased significantly (P Ͻ 0.001) during the first week of therapy (mean percentage of reduction in the AUC value was 49%). By adopting an intermittent dosing regimen, 1 week on/1 week off (1 course), at the start of courses 2 and 6, we obtained the ATRA AUCs equivalent to the ones achieved on day 1 of course 1. A marked inter-individual variability in the main ATRA pharmacokinetic parameters was observed in all of the patients studied and the extent of plasma increase in AUCs after 1 week without the drug administration was unpredictable. It is still not certain whether the higher plasma concentrations of ATRA, achieved by means of an alternate schedule, should be more effective than the ones of a chronic daily schedule. However, the clinical relevance of maintaining therapeutic ATRA plasma concentrations seems to be confirmed by the assessment of low plasma ATRA AUCs in APL patients at relapse when the drug was administered as maintenance therapy. These observations suggested that the acquired ATRA resistance could be related to the inability to sustain the intranuclear ATRA concentrations required to initiate differentiation.
In conclusion, our results first showed the effects of ATRA in Ph+ CML patients in chronic phase and provided useful information for planning future therapeutic trials with ATRA alone or in combinatiion with other agents including IFN␣. Although ATRA, as a single agent, appeared to be unable to induce in vivo relevant cytoreductive effects on the Ph+ clone, this observation does not rule out the possibility that it can induce differentiating effects and play a useful role in CML therapy when combined with other therapies. Since it has been noticed that in different leukemia cell lines ATRA can induce a remarkable upregulation of two IFN␣-responsive genes, interferon responsive factor 1 (IRF1) and 2′-5′ oligoadenylate synthetase, 29 the potential interactive effects of ATRA in combination with IFN␣ could be worth evaluating in CML. Due to the low cytotoxic activity, if ATRA was given in combination with IFN␣ and/or other cytotoxic agents, dose reduction of these would not be planned. However, on the basis of our pharmacokinetics results, ATRA should be administered intermittently rather than continuously.
